Jaswinder Singh, MD
Neurology · San Antonio, TXNPI 1831416262
Payments from drug & device makers
Across 67 payments — averaging $69.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Teva Pharmaceuticals USA, Inc.$589
- EMD Serono, Inc.$497
- UCB, Inc.$263
- Neurocrine Biosciences, Inc.$253
- Jazz Pharmaceuticals Inc.$193
- plus $2K from 19 others
What the payments were for
- Travel & lodging$83018%
- Food & beverage$3,43274%
- Education$4059%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $1,193 |
| Teva Pharmaceuticals USA, Inc. | 6 | $589 |
| EMD Serono, Inc. | 8 | $497 |
| UCB, Inc. | 5 | $263 |
| Neurocrine Biosciences, Inc. | 2 | $253 |
| Jazz Pharmaceuticals Inc. | 2 | $193 |
| Medtronic | 1 | $178 |
| Neuropace, Inc. | 1 | $178 |
| Abbott | 1 | $176 |
| Biogen | 4 | $154 |
| AstraZeneca | 2 | $153 |
| SK Life Science, Inc. | 1 | $135 |
| TG Therapeutics, Inc. | 1 | $127 |
| MDD US Operations, LLC | 3 | $113 |
| Bristol Myers Squibb | 1 | $88 |
| Gilead | 4 | $84 |
| Acadia Pharmaceuticals Inc | 1 | $57 |
| Springworks Therapeutics, Inc. | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $46 |
| Aucta Pharmaceuticals, Inc. | 5 | $36 |
| AbbVie | 1 | $26 |
| Pfizer | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$817
- Mavenclad$253
- Austedo XR$250
- ACTIVA$178
- RNS Neurostimulator Kit$178
- Proclaim IPG$176
- XCOPRI$135
- ONGENTYS$128
- BRIUMVI$127
- INGREZZA$125
- AJOVY$123
- GENERAL DBS$121
How this compares
$4,667 in reported general payments places this provider in the 55th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide ErPyridostigmine Bromide | 16 | $4,708 |
| Levetiracetam | 152 | $3,829 |
| Memantine Hcl | 136 | $3,765 |
| Lacosamide | 41 | $2,560 |
| Primidone | 180 | $2,268 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 163 | $2,144 |
| Carbamazepine ErCarbamazepine | 38 | $1,933 |
| Amitriptyline Hcl | 258 | $1,841 |
| Levetiracetam ErLevetiracetam | 16 | $1,821 |
| Oxcarbazepine | 22 | $1,725 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 39 | $1,313 |
| Clobazam | 24 | $1,191 |
| Pyridostigmine Bromide | 15 | $1,187 |
| Divalproex Sodium | 48 | $962 |
| Donepezil Hcl | 136 | $913 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Antonio
- Ann BassSan Antonio$12.3M
- Juan Ramirez CastanedaSan Antonio$1.1M
- Eleni VaouSan Antonio$584K
- Rebecca RomeroSan Antonio$569K
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.